Geron | GERN - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
Amgen USD 4.68B 65M 2026-09
Bio Techne USD 95M 19.5M 2026-06
Cassava Sciences USD -9.39M 1.78M 2026-06
Cytokinetics USD -167.09M 12.08M 2026-09
Exelixis USD 268.42M 20.01M 2026-09
Genmab DKK 407M 182M 2026-06
Geron USD 5.73M 18.38M 2026-09
Gilead Sciences USD 3.85B 1.17B 2026-06
Incyte USD -707.47M 1.41B 2026-09
MacroGenics USD -13.85M 19.59M 2026-06
Novartis USD 5.14B 392M 2026-09
Novavax USD 20.94M 100.32M 2025-12